Immune infiltration landscape and potential drug-targeted implications for hepatocellular carcinoma with ‘progression/hyper-progression’ recurrence
Three primary immunotypes of resectable HCC (IE2, ITM and ID) were identified, and HG and lenvatinib could potentially overcome immune checkpoint blockade (ICB) resistance in ITM patients with HCC, particularly those classified as type III-IV.
Authors
- Yi-Yue Huang
- Zu-Shun Chen
- Yuangang Su (ORCID: https://orcid.org/0000-0002-1308-2688)
- Jing‐Xuan Xu (ORCID: https://orcid.org/0000-0002-5516-4948)
- Lu‐Nan Qi (ORCID: https://orcid.org/0000-0003-2538-9748)
- Yuchong Peng
- Yuanyuan Chen (ORCID: https://orcid.org/0000-0002-9873-7902)
Institutions
- Ministry of Education of the People's Republic of China (CN)
- Guangxi Medical University (CN)
- First Affiliated Hospital of GuangXi Medical University (CN)
- First People's Hospital of Chongqing (CN)
Publication Details
- Journal
- Annals of Medicine
- Published
- 2025-01-27
- DOI
- https://doi.org/10.1080/07853890.2025.2456113
- Citations
- 2
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 2.09
Funders
- National Natural Science Foundation of China